Cosopt Versus Xalacom

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00273481

Enrollment

Registered

2006-01-09

Start date

2005-09-30

Completion date

2007-04-30

Last updated

2008-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-Angle Glaucoma, Ocular Hypertension

Brief summary

To compare the intraocular pressure efficacy and safety of the DTFC given twice daily versus the LTFC given once every morning following a run-in period with timolol maleate given twice daily.

Interventions

DRUGdorzolamide 2%/timolol maleate 0.5% fixed combination

DRUGlatanoprost 0.005%/timolol maleate 0.5% fixed combination

DRUGtimolol maleate 0.5%

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adults with primary open-angle or pigment-dispersion glaucoma, or ocular hypertension * at baseline the intraocular pressure should be 20 to 32 mm Hg inclusive at 08:00 measurement (Visit 2) after dosing with timolol the evening before * the intraocular pressure should be 32 mm Hg or less at all the time points in both eyes at Visit 2 * visual acuity should be 6/60 or better in the study eye(s)

Exclusion criteria

* any anticipated change in systemic hypotensive therapy during the trial * use of any corticosteroids by any route for more than two weeks during the study * contraindications to study medicines

Countries

Canada, Slovenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026